Cytokinetics Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Cytokinetics stock has a consensus rating of "Buy" and an average price target of $107.8. The average 1-year stock price forecast is 25.99% higher than the current stock price, while the lowest is $83 (-2.99%) and the highest is $146 (+70.64%).

Price Target: $107.8 (+25.99%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$83	$107.8	$105	$146
Change	-2.99%	+25.99%	+22.72%	+70.64%

Analyst Ratings

The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	10	10	11	12	13	13
Buy	7	7	7	7	7	7
Hold	3	3	3	3	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	20	21	22	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Leonid Timashev RBC Capital	RBC Capital	Buy Maintains $119 → $117	Buy	Maintains	$119 → $117	+36.75%	Jul 7, 2026
Ashwani Verma UBS	UBS	Buy Upgrades $115	Buy	Upgrades	$115	+34.41%	Jun 29, 2026
Serge Belanger Needham	Needham	Buy Maintains $102	Buy	Maintains	$102	+19.21%	Jun 29, 2026
Salim Syed Mizuho Securities	Mizuho Securities	Buy Maintains $100 → $118	Buy	Maintains	$100 → $118	+37.91%	Jun 23, 2026
Eric Joseph Citi	Citi	Buy Reiterates $99	Buy	Reiterates	$99	+15.71%	Jun 17, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

111.15M

from 88.04M

26.25%

from 88.04M

Revenue Next Year

393.06M

from 111.15M

253.62%

from 111.15M

EPS This Year

-6.32

from -6.54

EPS Next Year

-4.67

from -6.32

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	70.43M	94.59M	7.53M	18.47M	88.04M	111.15M
Revenue Growth	26.15%	34.31%	-92.04%	145.34%	376.56%	26.25%
Operating Income	-186.31M	-324.20M	-496.21M	-536.25M	-612.26M	-746.99M
Net Income	-215.31M	-388.96M	-526.24M	-589.53M	-784.96M	-799.17M
EPS	-	-	-	-	-6.54	-6.32
Free Cash Flow	-179.83M	-127.01M	-260.37M	-241.29M	-379.62M	-661.35M
No. Analysts	-	-	-	-	-	21

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	182.4M
Avg	111.2M
Low	76.7M

Revenue Growth

Revenue Growth	2026	2027	2028
High	107.1%
Avg	26.3%
Low	-12.9%

EPS Forecast

EPS	2026	2027	2028
High	-4.80
Avg	-6.32
Low	-7.47

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-